User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.
The user experienced anxiety and side effects from topical finasteride and is considering switching to saw palmetto. Another user reported no improvement with saw palmetto and experienced liver issues.
A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.
The user is considering trying finasteride again for hair loss despite past side effects like tender nipples and concerns about mental health impacts. They are advised to consult a doctor and consider topical or low-dose finasteride.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
User is impressed with 3-month progress using Hims oral finasteride, minoxidil, and biotin. Encouragement to view hair loss treatment as a long-term strategy.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user experienced hair thinning possibly due to excess vitamin A from taking extra gummy vitamins. They stopped taking the vitamins and are seeking advice on hair regrowth and managing vitamin A levels.
Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
A user is considering switching from oral to topical treatments for hair loss due to side effects like watery semen and erectile dysfunction. They are currently using oral finasteride and minoxidil and are concerned about potential sexual side effects with topical use.
The conversation discusses the potential use of thermal paper receipts, which contain estrogen, as a treatment for hair loss. Participants humorously debate its effectiveness compared to established treatments like Minoxidil and finasteride.
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Parabens in Minoxidil are a concern for some users due to potential health risks. The conversation discusses the presence of methylparaben and propylparaben in a specific Minoxidil brand, Ylox.
People worrying about hair loss and the effects of Finasteride on erections, which a transgirl has experienced no change from taking it with other medications. The discussion suggests that people should stop worrying so much.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The conclusion of the conversation is that the user, Michael_Scott1234, has been using topical minoxidil for a long time and recently started using oral finasteride and dermarolling. They have not experienced any side effects from finasteride and are happy with their progress.
A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.
The user "Potvin_Sucks_" shared their positive experience with using finasteride pills for hair loss. They also mentioned making lifestyle changes such as quitting smoking and exercising regularly. Other users discussed the possibility of using topical finasteride and online hair loss prescription delivery services.
The conversation is about a user's progress with an oral treatment for hair loss using a stack of finasteride, minoxidil, and biotin over two months, noting stabilization after an initial shed. The user mentions using Hims Chews, which are effective but costly, and another user comments that biotin is ineffective.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.